Akero Therapeutics (AKRO) said Monday it has started an underwritten public offering of $300 million of shares, with J.P. Morgan, Morgan Stanley and Jefferies as book-running managers.
The underwriters will be given a 30-day option to buy up to an additional $45 million of shares, the clinical-stage company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.